xinbang phar.(SZ:002390)2022-12-03 09:04Group 1: Investor Relations Activity - The investor relations activity included a visit to the tumor hospital and presentations by company executives [2][3] - The event was attended by 15 investors registered through Huachuang Securities and representatives from various regulatory bodies [2] - The meeting took place on December 6, 2018, from 9:30 AM to 12:00 PM at the company's administrative office [2] Group 2: Financial Performance and Challenges - The company's cash flow from operating activities was negative in the first half of 2018, primarily due to increased prepayments for pharmaceuticals following the implementation of the "two-invoice system" [3] - Revenue from the pharmaceutical distribution business increased by 21.05% compared to the previous year [3] Group 3: Business Strategy and Future Plans - The company maintains its strategic direction and management team despite changes in the controlling shareholder [3][4] - The three main business segments are pharmaceutical distribution, medical services, and pharmaceutical manufacturing, with distribution being the largest [4] - Future investments will focus on enhancing medical services to meet market demand and achieve synergy among the three business segments [4] Group 4: Clinical Trials and Market Presence - The tumor hospital has obtained qualifications for drug clinical trials, which aligns with the company's goal of becoming a "high-tech medical service group" [4] - The company has developed over 30 drug abuse testing kits, including fentanyl testing kits, which have been well-received in the European and American markets [5] Group 5: Investor Communication and Market Stability - The company utilizes various channels for investor communication, including on-site research, interactive platforms, and social media [5] - In the first half of 2018, the company implemented share buybacks and encouraged employees to increase their holdings to stabilize the market [5]